RARECYTE INC.

In News

RareCyte Expands Clinical-Scale Spatial Proteomics Portfolio with New Orion Systems and Leadership Appointment - BioSpace

BioSpace - Apr 20, 2026

RareCyte® announces research grant to investigate molecular profile of circulating trophoblasts in fetal growth restriction - Drug Discovery News

Drug Discovery News - Aug 26, 2025

Evaluating Combinatorial Targets for Precision Therapeutics: A Pathologist’s View - Fierce Pharma

Fierce Pharma - Oct 08, 2026

Open source software for multiplex staining & image analysis - Select Science

Select Science - Oct 23, 2024

High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers - Nature

Nature - Jun 22, 2023

Spatial Biology Market Analysis and Forecast, 2025-2035: Stellaromics, RareCyte, and 10x Genomics Drive Innovation and Funding Momentum - Yahoo Finance UK

Yahoo Finance UK - Nov 20, 2025

New test might expand ability to find tumor cells in blood - UW Medicine | Newsroom

UW Medicine | Newsroom - Jun 21, 2023

Liquid biopsy startup RareCyte announces $30M round and new CEO to fuel rare cell detection - GeekWire

GeekWire - Aug 29, 2017

Identification and characterization of effusion tumor cells (ETCs) from remnant pleural effusion specimens - Wiley & Sons

Wiley & Sons - Jun 25, 2021

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment